CN101548993B - Application of Japanese climbing fern spore in preparing lead excretion medicines or health products - Google Patents
Application of Japanese climbing fern spore in preparing lead excretion medicines or health products Download PDFInfo
- Publication number
- CN101548993B CN101548993B CN2009100114105A CN200910011410A CN101548993B CN 101548993 B CN101548993 B CN 101548993B CN 2009100114105 A CN2009100114105 A CN 2009100114105A CN 200910011410 A CN200910011410 A CN 200910011410A CN 101548993 B CN101548993 B CN 101548993B
- Authority
- CN
- China
- Prior art keywords
- lead
- medicines
- medicine
- spora lygodii
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses new application of Japanese climbing fern spore in preparing lead excretion medicines or health products. The Japanese climbing fern spore can be prepared into medicines or health products for people with high lead.
Description
Technical field
The raw material that the present invention relates to is the Chinese medicine Spora Lygodii, is the medicine of lead-eliminating effect in preparation promotes body and the purposes in the health product specifically.
Background technology
Lead is a kind of human body non-essential element, it has very strong affinity to body tissue, and by influencing the element of needed by human, upset the physiology combination of indispensable element in the human body and the balance of proportionate relationship, thereby the physiologically active of enzyme system and biomacromolecule in the upset body, make in the body enzyme system lose normal physiological activity and other and regulate the equilibrated regulating action of body functions and get muddled, and then influence a plurality of systems of human body.Plumbous ideal concentration is zero in blood.Yet along with the acceleration of urbanization and process of industrialization, the environment lead contamination is on the rise, even has influence on human beings'health.Lead in the environment can enter human body by respiratory tract and skin, and is distributed in whole body with the form of phosphoric acid hydrogen lead, wherein has 90-95% to be converted into orthophosphate and is deposited in skeleton, tooth, internal organs, skin, the hair, transfers in the blood lentamente then.Each tissue system of human body all there is harm, wherein responsive to lead with nervous system and hemopoietic system.Be embodied in: influence the growth and the skeleton development of intelligence, cause dyspepsia and endocrine disturbance, cause anemia, hypertension and arrhythmia, destroy renal function and immunologic function etc.In addition, lead also has carcinogenic effect.
According to statistics, the U.S. is during 1979-1998, and once report had 200 people to die from lead poisoning, and the male has accounted for 74%, and the Afro American has accounted for and accounts for 76% more than 67%, 45 years old, and southerner has accounted for 70%.World Health Organization (WHO) child hygiene cooperation center and Beijing Shoudu Inst. of Pediatrics have carried out the investigation in 3 years by a definite date, have monitored 45462 of 23 city 0-6 year children.The result shows: 23 average Pb-Bs in urban children of 2004-2006 are 56.66ug/L to 59.52ug/L, and are ascendant trend year by year.Different cities lead levels and the shared ratio of high Pb-B child there are differences, and there are Yinchuan, Chengdu, Haikou, Guangzhou, Zhengzhou, Hefei, Wuhan in the city that is higher than 15 city 3 annual Pb-Bs.According to international children ' s lead poisoning diagnostic criteria (blood lead value＞100ug/L), China's urban children lead poisoning prevalence rate is between 30%-40%, part urban industry contaminated area nearly 100% even there is not the common urban district of obvious industrial pollution, also has the children blood lead of 10%-30% to exceed standard.Plumbous potential hazard to health causes people's attention day by day.
At present, preventing and treating saturnine basic principle is that environment intervention, health education and clinical treatment three combine, and the environment intervention is basic, and health education is a basic means, and the lead poisoning more than the moderate is just considered Drug therapy.The saturnine medicine of clinical treatment mainly contains calcium disodium chelate (CaNa2EDTA), sodium dimercaptosuccinate (DMSA) etc., though driving lead, these medicines can reduce lead load in the body, Plumbum removing is effective, but micro elements needed by human is run off, also can cause damage to kidney, side effect is bigger, and drives nervous lesion that plumbous medicine causes lead and reverse and have little significance, so outside the medicine Plumbum removing a good appetite suddenly appearing in a serious disease severe lead poisoning, clinically generally do not adopt.Also there are some to propose, and obtained certain curative effect, can be used for light, the moderate lead poisoning of prevention or treatment with dietetic therapy or Chinese medicine Plumbum removing.
Spora Lygodii Lygodium japonicum (Thunb.) Sw. is the perennial herbaceous plant that climbs up by holding on to, and its ripe spore and herb all can be used as medicine.Be born in hillside thick grass or the bushes.Main product in Guangdong, Zhejiang, all produce national the greater part.Chinese medicine thinks that it has eliminating damp-heat, the effect for the treatment of stranguria pain relieving, clinical pyretic stranguria, sand Stranguria, stranguria with blood, stranguria marked by chyluria, the Urethra astringent pain etc. of being mainly used in.Modern pharmacology discovers that its preparation has the effect of diuresis and expelling stone, function of gallbladder promoting, and its decoct all has inhibitory action to staphylococcus aureus, bacillus pyocyaneus, shigella flexneri, Bacillus typhi.Clinical report, the bright leaf of Spora Lygodii is mashed external application with spore, can treat herpes zoster; Add yellow wine, water half and half decoction, treat acute breast carcinoma etc.Its dry ratan has the effect of heat-clearing and toxic substances removing, can be used for carbuncle pyogenic infections from tumour or sore, mumps and jaundice due to damp-heat etc.
Chinese invention patent publication number CN101085321 discloses " a kind of Chinese medicine preparation for the treatment of lithangiuria ", adopting 10 Chinese medicine medicines such as Herba Lysimachiae, Spora Lygodii, Rhizoma Corydalis and Radix Cyathulae is that feedstock production has clearing away heat-damp and promoting diuresis, the Chinese medicine preparation of Tonglin Paishi effect.Chinese invention patent publication number CN11056815 discloses " a kind of method with Spora Lygodii preparation oral liquid ", and adopting Spora Lygodii and Semen Cucurbitae is the oral liquid that the effective ingredient preparation has parasite killing, anthelmintic, removing food stagnancy, digestion promoting function.Chinese invention patent publication number CN200710118399.3 discloses " Chinese medicine composition of treatment diabetes gallstone ", be combined to form with 10 Chinese medicine medicines such as Spora Lygodii, Semen Raphani (parched), Herba Taraxaci magnolia obovatas and have relieving depressed liver and clearing heat, the Chinese medicine composition of regulating QI to relieve pain effect is used for the treatment of diabetes gallstone.Chinese invention patent publication number CN200710015847.7 discloses " Chinese medicinal formulae of treatment stomachache ", discloses a kind of Chinese medicinal formulae for the treatment of stomachache, by Spora Lygodii, Herba Taraxaci, Endoconcha Sepiae, configurations such as Rhizoma Cyperi form, and can be used for treating gastritis, gastric ulcer, duodenal ulcer.
Promote the effect of human body Plumbum removing to yet there are no bibliographical information but whether Spora Lygodii or its extract have.
Summary of the invention
The object of the invention provides Spora Lygodii or its extract promotes the medicine of lead-eliminating effect or the application in the health product in preparation.
The extract of the ripe spore of employing Spora Lygodii and/or the ripe spore of its herb or Spora Lygodii and/or its herb is as raw material, list is used or is promoted the lead-eliminating effect drug regimen with other, the preparation method of preparation is prepared into the medicine or the health product that are fit to oral any dosage form routinely.Wherein, other promote that lead-eliminating effect medicines can be one or more the combinations of Fructus Lycii, Flos Chrysanthemi, Herba Scutellariae Barbatae, Poria, Radix Salviae Miltiorrhizae, Rhizoma Atractylodis or Rhizoma Alismatis.
The present invention has filtered out from numerous Chinese medicines and has had the Spora Lygodii that clearly promotes lead-eliminating effect.Employing Spora Lygodii or its extract list are used or are promoted the lead-eliminating effect drug regimen with other, the medicine or the health product of preparation, can reach and promote the plumbous purpose of human body being damaged, improves symptom of Plumbum removing, alleviation or prevention, and have no side effect, be suitable for the higher crowd of blood lead and take for a long time, also be suitable for the higher child of blood lead.
The specific embodiment
The invention will be further elaborated below in conjunction with embodiment.
Embodiment 1
50 healthy Kunming mouses, cleaning level, male female half and half, body weight 20 ± 2g is divided into 5 groups, and promptly the blank group is dyed plumbous model group, 3 dosage groups of high, medium and low Spora Lygodii herb decocting liquid, 10 every group.Lead acetate is dissolved in the distilled water by the 40mg/kg lumbar injection, sets up mice and dye plumbous animal model.
Spora Lygodii herb decocting liquid adopts conventional decocting method preparation, concentrates, and decocting liquid various dose group comprises high dose group (9g/kg), middle dosage group (6g/kg), low dose group (3g/kg), gastric infusion is respectively organized in medication, all the other each groups gavage the normal saline of equivalent, and the experiment successive administration is totally 6 weeks.Administration is got mice right femoral vein blood 40ul after finishing, and puts into the plastic centrifuge tube with cover that fills 0.36ml 1% nitric acid and shakes up; Get a side 50% femur, digest after weighing, add rare nitric acid and be settled to 5ml, and get liver and cerebral tissue, with atomic spectrophotometer carry out blood and bone, liver, the brain lead content is measured.Data statistics is checked with T.
Table 1 Spora Lygodii herb decocting liquid to mice blood lead, bone lead, liver and brain lead (mg/kg) content influence (x ± s, n=10)
aCompare P＜0.05 with model group
bCompare P＜0.01 with the blank group
Spora Lygodii herb decocting liquid can reduce and dyes the plumbous regulating liver-QI lead content of plumbous mice blood lead, bone lead, brain, wherein with high, the effect of middle dosage water decocting liquid is comparatively obvious, relatively blood lead, bone lead, the plumbous regulating liver-QI lead content of brain reduce obviously P＜0.05 with model group.
Embodiment 2
50 healthy Kunming mouses, cleaning level, male female half and half, body weight 20 ± 2g is divided into 5 groups, and promptly the blank group is dyed plumbous model group, 3 dosage groups of high, medium and low Spora Lygodii herb decocting liquid, 10 every group.Lead acetate is dissolved in the distilled water by the 40mg/kg lumbar injection, sets up mice and dye plumbous animal model.
Take by weighing Spora Lygodii powder (ripe spore and herb are beaten powder with weight ratio and made) and Flos Chrysanthemi by same weight proportion, adopt conventional decocting method to prepare Spora Lygodii Flos Chrysanthemi decocting liquid, concentrate, each medication group gastric infusion, the various dose group comprises high dose group (9g/kg), middle dosage group (6g/kg), and low dose group (3g/kg) is gastric infusion respectively, all the other each groups gavage the equivalent normal saline, and the experiment successive administration is totally 6 weeks.Administration is got mice right femoral vein blood 40ul after finishing, and puts into the plastic centrifuge tube with cover that fills 0.36ml 1% nitric acid and shakes up; Get a side 50% femur, digest after weighing, add rare nitric acid and be settled to 5ml, with corresponding liver and the cerebral tissue got of method, with atomic spectrophotometer carry out blood and bone, liver, the brain lead content is measured.Data statistics is checked with T.
Table 2 Spora Lygodii Flos Chrysanthemi decocting liquid to mice blood lead, bone lead, liver and brain lead (mg/kg) content influence (x ± s, n=10)
aCompare P＜0.05 with model group
bCompare P＜0.01 with the blank group
Spora Lygodii Flos Chrysanthemi decocting liquid can reduce and dyes the plumbous regulating liver-QI lead content of plumbous mice blood lead, bone lead, brain, wherein with high, the effect of middle dosage water decocting liquid is comparatively obvious, relatively blood lead, bone lead, the plumbous regulating liver-QI lead content of brain reduce obviously P＜0.05 with model group.
Claims (2)
1. Spora Lygodii or its decocting liquid list are used or are promoted lead-eliminating effect medicines to promote the medicine of lead-eliminating effect or the application in the health product in preparation with other,
Wherein, described other promote that the lead-eliminating effect medicine is one or more in Fructus Lycii, Flos Chrysanthemi, Herba Scutellariae Barbatae, Poria, Radix Salviae Miltiorrhizae, Rhizoma Atractylodis, the Rhizoma Alismatis.
2. application according to claim 1, medicine wherein or health product are peroral dosage form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100114105A CN101548993B (en) | 2009-05-06 | 2009-05-06 | Application of Japanese climbing fern spore in preparing lead excretion medicines or health products |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100114105A CN101548993B (en) | 2009-05-06 | 2009-05-06 | Application of Japanese climbing fern spore in preparing lead excretion medicines or health products |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101548993A CN101548993A (en) | 2009-10-07 |
| CN101548993B true CN101548993B (en) | 2011-09-21 |
Family
ID=41153636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100114105A Expired - Fee Related CN101548993B (en) | 2009-05-06 | 2009-05-06 | Application of Japanese climbing fern spore in preparing lead excretion medicines or health products |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101548993B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102258628B (en) * | 2011-07-19 | 2012-11-07 | 辽宁大学 | Chinese medicinal composition with lead removal promoting effect |
| CN102727757B (en) * | 2012-07-06 | 2014-12-10 | 辽宁大学 | Application of Chinese Ladiestresses Root or Herb in preparation of either medicines or healthcare products capable of promoting lead-expelling effect |
| CN102935132B (en) * | 2012-09-04 | 2013-12-18 | 辽宁大学 | Lead removing traditional Chinese medicine composition |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1654043A (en) * | 2004-02-12 | 2005-08-17 | 顾荣伟 | Method for preparing pure Chinese medicinal single prescription aqua agent and use thereof |
-
2009
- 2009-05-06 CN CN2009100114105A patent/CN101548993B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1654043A (en) * | 2004-02-12 | 2005-08-17 | 顾荣伟 | Method for preparing pure Chinese medicinal single prescription aqua agent and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101548993A (en) | 2009-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101961464B (en) | Chinese medicinal composition for treating jaundice and preparation method thereof | |
| CN102048933A (en) | Chinese medicinal composition for treating infantile diarrhea and preparation method thereof | |
| CN102205107B (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN101548993B (en) | Application of Japanese climbing fern spore in preparing lead excretion medicines or health products | |
| CN102258628B (en) | Chinese medicinal composition with lead removal promoting effect | |
| CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
| CN102988631B (en) | Chinese medicinal preparation for treating epilepsia | |
| CN102657811B (en) | Orally administered liquid for treating canker sore | |
| CN100525801C (en) | Application of plantain herb in preparing medicine and health article with lead removal promoting effect | |
| CN104524479B (en) | A kind of Chinese medicine composition for treating premenstrual syndrome and preparation method thereof | |
| CN1192789C (en) | 'Shenhuaxiaokecha' tea and preparing method thereof | |
| CN103007145B (en) | Traditional Chinese medicine composition for treating children rotavirus enteritis and preparation method of composition | |
| CN102813757B (en) | Preparation method of traditional Chinese medicine for treating lumbago type acute glomerulonephritis | |
| CN100394930C (en) | Application of cassia seed in preparation of lead-remove promoting drug or health-caring product | |
| CN103750304A (en) | Weight-reducing, fat-reducing and health-protection rhizoma alismatis oral liquid and preparation method thereof | |
| CN101288683A (en) | Application of roselle for preparing health product for promoting lead-eliminating effect | |
| CN102793826B (en) | Traditional Chinese medicine for treating hypertension early-stage kidney damage and preparation method thereof | |
| CN102727757B (en) | Application of Chinese Ladiestresses Root or Herb in preparation of either medicines or healthcare products capable of promoting lead-expelling effect | |
| CN102727618B (en) | Application of Caulis et Folium Hedyotis Hedyotideae in preparation of drug or health product for promoting lead removing | |
| CN105943860A (en) | Medicine preparation for treating diabetes mellitus and preparation method thereof | |
| CN105055658A (en) | Medicine for treating liver meridian damp-heat type infantile enuresis and preparation method thereof | |
| CN104587017A (en) | Pharmaceutical composition for clearing heat and relaxing bowels, promoting qi and activating blood circulation as well as preparation method and application of pharmaceutical composition | |
| CN103977046A (en) | Composition for promoting lead removal | |
| CN102302569B (en) | Chinese medicinal composition for promoting lead discharging effect | |
| CN116549579A (en) | Preparation method of drug for treating uremia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110921 Termination date: 20140506 |